ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

Luca Moscetti, Lucia Mentuccia, Patrizia Vici, Silvia Quadrini, Isabella Sperduti, Laura Pizzuti, Maria Agnese Fabbri, Angela Vaccaro, Marcello Maugeri-Saccà, Maddalena Barba, Domenico Sergi, Germano Zampa, Teresa Gamucci

Research output: Contribution to journalArticle

Abstract

AIM: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations.

PATIENTS & METHODS: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires.

RESULTS: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores.

CONCLUSION: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.

Original languageEnglish
Pages (from-to)1517-1525
Number of pages9
JournalFuture Oncology
Volume13
Issue number17
DOIs
Publication statusPublished - Jul 2017

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study'. Together they form a unique fingerprint.

  • Cite this

    Moscetti, L., Mentuccia, L., Vici, P., Quadrini, S., Sperduti, I., Pizzuti, L., Fabbri, M. A., Vaccaro, A., Maugeri-Saccà, M., Barba, M., Sergi, D., Zampa, G., & Gamucci, T. (2017). ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. Future Oncology, 13(17), 1517-1525. https://doi.org/10.2217/fon-2017-0062